Evolent Health earnings release, August 6, 2026

Evolent Health, Inc. (EVH) · Form 8-K, Item 2.02 · Filed · SEC filing

Evolent Announces Second Quarter 2026 Results

WASHINGTON (August 6, 2026) – Evolent Health, Inc. (NYSE: EVH) (“Evolent” or the “Company”), a company that specializes in better health outcomes for people with complex conditions through proven solutions that make health care simpler and more affordable, today announced financial results for the three months ended June 30, 2026.

Seth Blackley, Co-Founder and Chief Executive Officer of Evolent stated, “We believe our results for the second quarter of 2026, our updated 2026 guidance and our 2027 outlook all demonstrate that Evolent is delivering strong growth, profitability and cash flow. We are confident in our emerging AI-led operational model that we believe allows us to deliver excellent client and clinical outcomes, while being highly disciplined with our cost structure."

Mario Ramos, Chief Financial Officer of Evolent stated, “Looking ahead to 2027, based on contracts in place today, upcoming launches scheduled and the strong continuing demand for our oncology solution, we expect to see revenue growth of over 25% compared to 2026. We expect the midpoint of our 2027 Adjusted EBITDA outlook will be at or above $150 million driven by expected improved Performance Suite care margins and a strong focus on expense reductions, despite significant continued industry headwinds from Medicaid and other client specific membership attrition. We also expect improved cash flow conversion, which, together with targeted debt reduction initiatives we are currently evaluating, we believe provides a clear path to addressing our capital structure and enhancing financial flexibility."

Highlights include (dollars in thousands, except for average PMPM fees and revenue per case):¹

The rising medical costs impacting health plans continue to drive robust demand for Evolent’s complex specialty care solutions.

Evolent has two partnership announcements, bringing the year-to-date total to four:

• First, we are preparing for the go live of an Oncology Performance Suite partnership with an existing advanced imaging client. The partnership will cover approximately 1.5 million lives across Medicaid and Medicare populations spread through 11 states. We currently expect this business to launch by December 2026, subject to certain regulatory approvals, and generate approximately $300 million in annualized revenue. As with other recent Performance Suite arrangements, this relationship includes Evolent’s full enhanced contractual protections.

• Second, an existing Specialty Technology & Services Suite client, a regional Blues plan customer, has signed an agreement to broaden its use of our Specialty Technology & Services Suite by adding new products and extending existing solutions to additional populations. We expect these implementations to occur during the third and fourth quarters of this year and annualized revenue from this contract to be less than $5 million.

Financial Results of Evolent Health, Inc.

In our earnings releases, prepared remarks, conference calls, slide presentations and webcasts, we may use or discuss financial measures not prepared in accordance with generally accepted accounting principles (“GAAP”). Definitions of the non-GAAP financial measures as well as reconciliations of non-GAAP financial measures to the most directly comparable GAAP financial measures are presented herein. See “Non-GAAP Financial Measures” for more information.

Reported Results

Evolent Health, Inc. reported the following results in accordance with GAAP (dollars in thousands, except for per share data):

Total cash and cash equivalents was $115.7 million as of June 30, 2026.

Adjusted Results

Evolent Health, Inc. reported the following adjusted results (dollars in thousands, except for per share data):²

Business Outlook

The Company does not believe it can meaningfully reconcile guidance for non-GAAP Adjusted EBITDA to net income (loss) attributable to common shareholders of Evolent Health, Inc. because the Company cannot provide guidance for the more significant reconciling items between net income (loss) attributable to common shareholders of Evolent Health, Inc. and Adjusted EBITDA without unreasonable effort. This is due to the fact that future period non-GAAP guidance includes adjustments for items not indicative of our core operations, and as a result from changes to our business due to transactions and other events. Such items may, from time to time, include change in tax receivable agreement liability, other refinancing fees, gain (loss) from equity method investees, gain (loss) on repayment/extinguishment of debt, other income (expense), gain (loss) on disposal of non-strategic assets, goodwill impairments, right-of-use asset impairments, gain (loss) on lease terminations, stock-based compensation expense, severance costs and transaction-related costs. Such adjustments may be affected by changes in ongoing assumptions, judgments, as well as nonrecurring, unusual or unanticipated charges, expenses or gains (losses) or other items that may not directly correlate to the underlying performance of our business operations. The exact amount of these adjustments is not currently determinable but may be significant.

Full Year 2026 Guidance

Incorporating its year-to-date performance, the Company is raising its 2026 revenue guidance range to $2.6 to $2.7 billion. The Company also tightening its Adjusted EBITDA range to $120 to $135 million.

Additional Outlook Information

The Company expects to deploy $25 million to $30 million in cash for capitalized software development during 2026.... (truncated)ge Commission (“SEC”).

Web and Conference Call Information

Evolent Health, Inc. will hold a conference call to discuss its financial performance and related matters this morning, August 6, 2026, at 8:00 a.m., Eastern Time. To listen to a live broadcast via the internet and view the accompanying materials, please visit the Company's Investor Relations website at http://ir.evolent.com. To participate by telephone, dial (855) 940-9467, or (412) 317-6034 for international callers, and ask to join the “Evolent Health call.” Participants are advised to dial in at least fifteen minutes prior to the call to register. The call will be archived on the Company's website for one week and will be available beginning later this evening. Evolent invites all interested parties to attend the conference call.

About Evolent

Evolent specializes in better health outcomes for people with complex conditions through proven solutions that make health care simpler and more affordable. Evolent serves a national base of leading payers and providers and is consistently recognized as a top place to work in health care nationally. Learn more about how Evolent is changing the way health care is delivered by visiting evolent.com.³

Contacts: investorrelations@evolent.com

Definitions

Revenue Agreements

Evolent reports the number of new revenue agreements signed for Performance Suite, Specialty Technology and Services Suite, Administrative Services and Case-based products. A new revenue agreement includes incremental revenue to the Company reflecting contracts for services to both new partner entities, corporations or health plans as well as additional sales to existing partners. New revenue agreements may include incremental services, geographic, or line of business expansions or a combination thereof. The conversion of Specialty Technology and Services Suite contracts to Performance Suite are also included in this definition. The Company does not count renewals for existing scope, growth of membership within an existing contract scope or transaction-related purchase agreements, if applicable, in this metric.

Lives on Platform and Per Member Per Month (“PMPM”) Fee

Performance Suite Lives on Platform are calculated by summing monthly members covered for specialty care services for contracts not under ASO arrangements divided by the number of months in the period. Specialty Technology and Services Suite Lives on Platform are calculated by summing monthly members covered for oncology, cardiology, musculoskeletal, advanced imaging and other diagnostic specialty care services for contracts under ASO arrangements divided by the number of months in the period. Administrative Services Lives on Platform are calculated by summing monthly members covered for administrative services implementation and core performance services divided by the number of months in the period. Cases are calculated by summing the number of individuals receiving services through our surgery management and advanced care planning programs in a given period. Members covered for more than one category are counted in each category.

Performance Suite Average PMPM fee is defined as revenue pertaining to our Performance Suite during the period reported divided by Performance Suite Lives on Platform for the period divided by the number of months in the period. Specialty Technology and Services Suite Average PMPM fee is defined as revenue pertaining to the Specialty Technology and Services Suite during the period reported divided by Specialty Technology and Services Suite Lives on Platform for the period divided by the number of months in the period. Administrative Services Average PMPM fee is defined as revenue pertaining to the Administrative Services during the period reported divided by the Administrative Services Lives on Platform for the period divided by the number of months in the period. Revenue per Case is calculated by the revenue pertaining to surgery management and advanced care planning programs divided by the number of cases for a given period.

Average Unique Members are calculated by summing members covered by our Performance Suite, Specialty Technology and Services Suite and Administrative Services. In cases where partners cross between multiple solutions, we only capture members from the solution with the maximum number of members.

Management uses Lives on Platform, PMPM fees, Cases, Revenue per Case and Average Unique Members because we believe that they provide insight into the unit economics of our services. We believe that these measures are also useful to investors because they allow further insight into the period over period operational performance.

Medical Expense Ratio

Medical Expense Ratio (“MER”) is a key performance indicator used by management for purposes of monitoring operating performance and is calculated as GAAP total claims incurred related to our specialty care management services solution divided by GAAP revenue related to our Performance Suite. Management believes MER is useful to investors because it provides insight into the efficiency with which medical costs are managed relative to revenue and helps identify trends in the underlying performance. For periods prior to the consummation of the sale of Evolent Care Partners (“ECP”) in December 2025, we present non-GAAP MER excluding revenues from ECP because is not indicative of ongoing operations.⁴

Financial statements

Income Statement

For the Three Months Ended June 30, — Highlights include (dollars in thousands, except for average PMPM fees and revenue per case):

For the Three Months Ended June 30, – 2026For the Three Months Ended June 30, – 2025
Financial Results:Revenue652,520444,328
Financial Results:Net loss attributable to common shareholders of Evolent Health, Inc.-28,364-51,090
Financial Results:Net loss margin-4.3-11.5
Financial Results:Adjusted EBITDA28,05037,547
Financial Results:Adjusted EBITDA Margin4.38.5
Average Lives on Platform/Cases by Product TypePerformance Suite6,7156,490
Average Lives on Platform/Cases by Product TypeSpecialty Technology and Services Suite75,64177,019
Average Lives on Platform/Cases by Product TypeAdministrative Services1,1891,231
Average Lives on Platform/Cases by Product TypeCases1213
Average Lives on Platform/Cases by Product TypeAverage Unique Members39,95640,201
Average PMPM Fees/ Revenue per Case by Product TypePerformance Suite24.0513.76
Average PMPM Fees/ Revenue per Case by Product TypeSpecialty Technology and Services Suite0.340.35
Average PMPM Fees/ Revenue per Case by Product TypeAdministrative Services13.4615.13
Average PMPM Fees/ Revenue per Case by Product TypeCases3,6082,969

Income Statement

For the Three Months Ended June 30, — Evolent Health, Inc. reported the following results in accordance with GAAP (dollars in thousands, except for per share data):

For the Three Months Ended June 30, – 2026For the Three Months Ended June 30, – 2025
Revenue652,520444,328
Cost of revenue571,684343,943
Selling, general and administrative expenses68,83175,209
Net loss attributable to common shareholders of Evolent Health, Inc.-28,364-51,090
Net loss margin-4.3%-11.5%
Loss per share attributable to common shareholders of Evolent Health, Inc.Basic and diluted-0.25-0.44

Income Statement

For the Three Months Ended June 30, — Evolent Health, Inc. reported the following adjusted results (dollars in thousands, except for per share data):

For the Three Months Ended June 30, – 2026For the Three Months Ended June 30, – 2025
Adjusted cost of revenue570,989342,893
Adjusted selling, general and administrative expenses53,48163,888
Adjusted EBITDA28,05037,547
Adjusted EBITDA margin4.3%8.5%
Adjusted income (loss) attributable to common shareholders2,226-11,013
Adjusted income (loss) per share attributable to common shareholders:Basic and diluted0.02-0.1

Income Statement

For the Three Months Ended June 30, — (unaudited, in thousands, except per share data)

For the Three Months Ended June 30, – 2026For the Three Months Ended June 30, – 2025For the Six Months Ended June 30, – 2026For the Six Months Ended June 30, – 2025
Revenue652,520444,3281,148,766927,977
ExpensesCost of revenue571,684343,943984,156725,121
ExpensesSelling, general and administrative expenses68,83175,209141,649153,618
ExpensesDepreciation and amortization expenses21,56623,14143,12147,199
ExpensesLoss on lease termination1,906
ExpensesChange in fair value of contingent consideration3,2062,926
ExpensesOperating expenses662,081445,4991,168,926930,770
ExpensesOperating loss-9,561-1,171-20,160-2,793
ExpensesInterest income7031,0841,7172,358
ExpensesInterest expense-16,859-11,601-33,727-21,986
ExpensesGain (loss) from equity method investees-41197-52178
ExpensesLoss on option exercise-196-52,544
ExpensesExtinguishment of Series A Preferred Stock and other refinancing fees-9,000-9,000
ExpensesOther income (expense), net109-35851-83
ExpensesLoss before income taxes-25,649-20,722-51,371-83,870
ExpensesProvision for (benefit from) income taxes2,715-8253,625645
ExpensesLoss before preferred dividends and accretion of Series A Preferred Stock including excise tax-28,364-19,897-54,996-84,515
ExpensesDividends and accretion of Series A Preferred Stock-31,193-38,825
ExpensesNet loss attributable to common shareholders of Evolent Health, Inc.-28,364-51,090-54,996-123,340
Loss per common shareBasic and diluted-0.25-0.44-0.49-1.07
Weighted-average common shares outstandingBasic and diluted112,542115,882112,225115,600
Comprehensive lossNet loss attributable to common shareholders of Evolent Health, Inc.-28,364-51,090-54,996-123,340
Other comprehensive loss, net of taxes, related to:Foreign currency translation adjustment22-1,00246
Other comprehensive loss, net of taxes, related to:Total comprehensive loss attributable to common shareholders of Evolent Health, Inc.-28,364-51,068-55,998-123,294

Income Statement

(unaudited, in thousands)

Reconciliation of Adjusted Cost of Revenue to Cost of Revenue – For the Three Months Ended June 30, – 2026For the Three Months Ended June 30, – 2026Reconciliation of Adjusted Cost of Revenue to Cost of Revenue – For the Three Months Ended June 30, – 2025For the Three Months Ended June 30, – 2025Reconciliation of Adjusted Cost of Revenue to Cost of Revenue – For the Six Months Ended June 30, – 2026For the Six Months Ended June 30, – 2026Reconciliation of Adjusted Cost of Revenue to Cost of Revenue – For the Six Months Ended June 30, – 2025For the Six Months Ended June 30, – 2025
Cost of revenue571,684343,943984,156725,121
Less:Stock-based compensation6951,0501,2141,707
Less:Adjusted cost of revenue570,989342,893982,942723,414

Income Statement

For the Three Months Ended June 30, — (unaudited, in thousands except MER percentages)

For the Three Months Ended June 30, – 2026For the Three Months Ended June 30, – 2025For the Six Months Ended June 30, – 2026For the Six Months Ended June 30, – 2025
RevenuePerformance Suite484,503267,917807,806570,938
RevenueSpecialty Technology and Services Suite78,16181,401158,960164,222
RevenueAdministrative Services47,98955,88097,576113,071
RevenueCases41,86739,13084,42479,746
RevenueTotal revenue652,520444,3281,148,766927,977
Less:Revenue from Evolent Care Partners15,46973,268
Less:Performance Suite revenue less revenue from Evolent Care Partners484,503252,448807,806497,670
Less:Total claims incurred related to our specialty care management services solution461,520214,247763,297420,239
Less:Medical expense ratio95.38094.573.6
Less:Medical expense ratio excluding Evolent Care Partners95.384.994.584.4

Income Statement

For the Three Months Ended June 30, — (unaudited, in thousands)

For the Three Months Ended June 30, – 2026For the Three Months Ended June 30, – 2025For the Six Months Ended June 30, – 2026For the Six Months Ended June 30, – 2025
Net loss attributable to common shareholders of Evolent Health, Inc.-28,364-51,090-54,996-123,340
Net loss margin-4.3-11.5-4.8%-13.3%
Less:Interest income7031,0841,7172,358
Less:Interest expense-16,859-11,601-33,727-21,986
Less:Benefit from (provision for) income taxes-2,715825-3,625-645
Less:Depreciation and amortization expenses-21,566-23,141-43,121-47,199
Less:Extinguishment of Series A Preferred Stock and other refinancing fees-9,000-9,000
Less:Gain (loss) from equity method investees-41197-52178
Less:Loss on option exercise-196-52,544
Less:Change in fair value of contingent consideration-3,206-2,926
Less:Other income (expense), net109-35851-83
Less:Loss on lease termination-1,906
Less:Stock-based compensation expense-15,201-11,580-25,850-22,661
Less:Severance costs-275-791-275-1,805
Less:Dividends and accretion of Series A Preferred Stock-31,193-38,825
Less:Transaction-related costs-569-1,031-703
Less:Adjusted EBITDA28,05037,54750,11774,407
Less:Adjusted EBITDA margin4.38.54.48

Income Statement

For the Three Months Ended June 30, — (unaudited, in thousands, except per share data)

For the Three Months Ended June 30, – 2026For the Three Months Ended June 30, – 2025For the Six Months Ended June 30, – 2026For the Six Months Ended June 30, – 2025
Net loss attributable to common shareholders of Evolent Health, Inc.-28,364-51,090-54,996-123,340
Less:Loss from equity method investees-41197-52178
Less:Other income (expense), net109-35851-83
Less:Benefit from (provision for) income taxes-2,715825-3,625-645
Less:Change in fair value of contingent consideration-3,206-2,926
Less:Extinguishment of Series A Preferred Stock and other refinancing fees-9,000-9,000
Less:Loss on option exercise-196-52,544
Less:Purchase accounting adjustments-12,490-13,364-24,980-26,729
Less:Loss on lease termination-1,906
Less:Stock-based compensation expense-15,201-11,580-25,850-22,661
Less:Severance costs-275-791-275-1,805
Less:Transaction-related costs-569-1,031-703
Less:Tax impact (1)592-2,927-7-948
Less:Adjusted income (loss) attributable to common shareholders2,226-11,013-27-3,568
Loss per share attributable to common shareholdersBasic and diluted-0.25-0.44-0.49-1.07
Adjusted income (loss) per share attributable to common shareholdersBasic and diluted0.02-0.1-0.03
Weighted-average common sharesBasic and diluted112,542115,882112,225115,600

Balance Sheet

June 30, 2026 — (in thousands, except share data)

June 30, 2026 – (unaudited)December 31, 2025
Current assets:Cash and cash equivalents115,703151,856
Current assets:Restricted cash22,99026,134
Current assets:Accounts receivable, net449,118309,861
Current assets:Prepaid expenses and other current assets22,69918,521
Current assets:Total current assets610,510506,372
Current assets:Restricted cash2,7732,706
Current assets:Investments and equity method investees8,7648,966
Current assets:Property and equipment, net81,92180,785
Current assets:Right-of-use assets - operating2,7104,373
Current assets:Prepaid expenses and other noncurrent assets2,3083,078
Current assets:Contract cost assets14,04713,537
Current assets:Intangible assets, net554,427584,937
Current assets:Goodwill694,434694,482
Current assets:Total assets1,971,8941,899,236
Current liabilities:Accounts payable38,82359,776
Current liabilities:Accrued liabilities43,89765,755
Current liabilities:Operating lease liability - current1,54115,343

Cash Flow

For the Six Months Ended June 30, — (unaudited, in thousands)

For the Six Months Ended June 30, – 2026For the Six Months Ended June 30, – 2025
Cash Flows Used In Operating ActivitiesLoss before preferred dividends and accretion of Series A Preferred Stock-54,996-84,515
Adjustments to reconcile net loss to net cash and restricted cash used in operating activities:Change in fair value of contingent consideration2,926
Adjustments to reconcile net loss to net cash and restricted cash used in operating activities:Loss (gain) from equity method investees52-178
Adjustments to reconcile net loss to net cash and restricted cash used in operating activities:Extinguishment of Series A Preferred Stock and other refinancing fees9,000
Adjustments to reconcile net loss to net cash and restricted cash used in operating activities:Loss on option exercise52,544
Adjustments to reconcile net loss to net cash and restricted cash used in operating activities:Depreciation and amortization expenses43,12147,199
Adjustments to reconcile net loss to net cash and restricted cash used in operating activities:Stock-based compensation expense25,85022,661
Adjustments to reconcile net loss to net cash and restricted cash used in operating activities:Deferred tax benefit2,970-570
Adjustments to reconcile net loss to net cash and restricted cash used in operating activities:Amortization of contract cost assets2,0232,523
Adjustments to reconcile net loss to net cash and restricted cash used in operating activities:Amortization of deferred financing costs5,9302,403
Adjustments to reconcile net loss to net cash and restricted cash used in operating activities:Loss on lease termination1,906
Adjustments to reconcile net loss to net cash and restricted cash used in operating activities:Right-of-use operating assets1,663792
Changes in assets and liabilities, net of acquisitions:Accounts receivable, net and contract assets-139,25755,925
Changes in assets and liabilities, net of acquisitions:Prepaid expenses and other current and non-current assets-4,031-1,803
Changes in assets and liabilities, net of acquisitions:Contract cost assets-2,533-1,649
Changes in assets and liabilities, net of acquisitions:Accounts payable-17,81018,189
Changes in assets and liabilities, net of acquisitions:Accrued liabilities-22,350-5,867
Changes in assets and liabilities, net of acquisitions:Operating lease liabilities-15,194-20,973
Changes in assets and liabilities, net of acquisitions:Accrued compensation and employee benefits-22,0214,543
Changes in assets and liabilities, net of acquisitions:Deferred revenue5-174
Changes in assets and liabilities, net of acquisitions:Reserve for claims and performance-based arrangements186,202-131,454
Changes in assets and liabilities, net of acquisitions:Other long-term liabilities80803
Changes in assets and liabilities, net of acquisitions:Net cash and restricted cash used in operating activities-10,296-25,769
Cash Flows Used In Investing ActivitiesCash paid for asset acquisitions and business combinations-56,047
Cash Flows Used In Investing ActivitiesReturn of equity method investments150788
Cash Flows Used In Investing ActivitiesPurchases of investments and contributions to equity method investees-1,000
Cash Flows Used In Investing ActivitiesInvestments in internal-use software and purchases of property and equipment-13,255-17,365
Cash Flows Used In Investing ActivitiesNet cash and restricted cash used in investing activities-13,105-73,624
Cash Flows (Used In) Provided by Financing ActivitiesChanges in working capital balances related to claims processing-3,143-44,754
Cash Flows (Used In) Provided by Financing ActivitiesPayment of contingent consideration-1,000
Cash Flows (Used In) Provided by Financing ActivitiesProceeds from issuance of long-term debt, net of offering costs221,000
Cash Flows (Used In) Provided by Financing ActivitiesRepayment of debt-10,000-62,500
Cash Flows (Used In) Provided by Financing ActivitiesPayment of preferred dividends-9,198
Cash Flows (Used In) Provided by Financing ActivitiesTaxes withheld and paid for vesting of equity awards-1,823-4,621
Cash Flows (Used In) Provided by Financing ActivitiesNet cash and restricted cash (used in) provided by financing activities-14,96698,927

From SEC EDGAR. Analysis by Pear Digitals from the filing alone. Not investment advice. · Evolent Health earnings · Latest earnings · Markdown

Screener

Plans

Premium and Pro coming soon.

Log in

New here?

Join the waitlist

Pear FMV opens to everyone soon. We'll email you when it does.